The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of combination of pasireotide (SOM 230) plus gemcitabine in metastatic pancreatic cancer (MPC).
Richard D. Kim
Research Funding - Novartis
Helen Jump
No relevant relationships to disclose
Dung-Tsa Chen
No relevant relationships to disclose
William J. Fulp
No relevant relationships to disclose
David Shibata
No relevant relationships to disclose
Erin Siegel
No relevant relationships to disclose
Gregory M. Springett
No relevant relationships to disclose